A second open letter to NIH for revisions to CCP recommendations

Please help give immunocompromised individuals all the options we can get to fight COVID.

It is critical that clinicians remain aware of very high-titer COVID-19 convalescent plasma as an FDA-authorized therapy. It offers an advantage over pharmaceuticals in that it is produced real time and reflects the most recent variants circulating in the population.

Legum Professor Acute Care Neurology, Director Multisite Clinical Trials Johns Hopkins ICTR

We will likely need this tool

Brian Koffman MDCM (retired) MS Ed Co-Founder, Executive VP and Chief Medical Officer CLL Society, Inc.

Please help increase access to important therapeutic options, particularly for our immunocompromised population.

This is an important and lifesaving therapy

CCP would provide us an option for our patients who are immunocompromised.

This is a life-saving therapy!

John Snow Professor of Epidemiology Mailman School of Public Health Columbia University

Thx.